Copy to clipboard 
The American Academy of Orthopaedic Surgeons (AAOS) announced development of the AAOS Orthobiologics Registry (OBR), a disease and condition-focused registry designed to measure the long-term safety, efficacy, and real-world outcomes of orthobiologic therapies for patients diagnosed with knee osteoarthritis. The pilot program will begin with 10 participating sites, with plans for methodical expansion over the next three to five years.
The AAOS OBR directly addresses AAOS’ mission to provide the highest quality musculoskeletal care through evidence-based practice. Despite growing patient interest in orthobiologics, current AAOS guidelines call for additional research on orthobiologics use. While PRP treatments have shown promise in improving some patient-reported outcomes, existing studies have substantial limitations, including inconsistent reporting of treatment protocols and a lack of long-term data.
The registry will focus on patient-reported outcomes and longitudinal tracking, with unique attributes including:
- Research-focused registry design with patient consent
- Centralized follow-up for patient-reported outcome measures (PROMs) completion
- Linkage to the BARB Biorepository for biological sample analysis
- Integration with standardized hemoanalyzer configuration
- Detailed adherence protocol to ensure high-quality data collection
AAOS has partnered with Elimu Informatics and PatientIQ to develop the technical infrastructure for the OBR. Elimu provides analysis and design support, establishing the registry model using the AAOS Master Data Dictionary and tools, while PatientIQ has developed a cloud-based registry consistent with OBR data specifications that facilitate the input of procedure and patient-reported outcomes data.
The OBR is a unique offering within the AAOS family of registries, developed with support from the American Orthopaedic Society for Sports Medicine, the Arthroscopy Association of North America, and the Biologic Association.
In 2019, AAOS announced a strategic investment in the field of biologics. Over the following five years, the Academy prioritized research and development for a biologics-focused competency within its existing business. The focus of this effort has been to create evidence-based, unbiased information as tracked by the AAOS Biologics Dashboard; thought-leadership, position statements; and educational content to help shape and guide orthopaedic surgeons and their patients within this space.
The launch of the AAOS OBR represents the next phase of this commitment and comes at a pivotal time. The convergence of an aging population, rising obesity rates, and greater emphasis on staying active continues to drive demand for innovative orthobiologic treatment options. With over 18% of the population over age 55 experiencing symptomatic knee osteoarthritis3, the social and physical impact of this condition continues to be widespread.
The American Academy of Orthopaedic Surgeons (AAOS) announced development of the AAOS Orthobiologics Registry (OBR), a disease and condition-focused registry designed to measure the long-term safety, efficacy, and real-world outcomes of orthobiologic therapies for patients diagnosed with knee osteoarthritis. The pilot program will begin with 10...
The American Academy of Orthopaedic Surgeons (AAOS) announced development of the AAOS Orthobiologics Registry (OBR), a disease and condition-focused registry designed to measure the long-term safety, efficacy, and real-world outcomes of orthobiologic therapies for patients diagnosed with knee osteoarthritis. The pilot program will begin with 10 participating sites, with plans for methodical expansion over the next three to five years.
The AAOS OBR directly addresses AAOS’ mission to provide the highest quality musculoskeletal care through evidence-based practice. Despite growing patient interest in orthobiologics, current AAOS guidelines call for additional research on orthobiologics use. While PRP treatments have shown promise in improving some patient-reported outcomes, existing studies have substantial limitations, including inconsistent reporting of treatment protocols and a lack of long-term data.
The registry will focus on patient-reported outcomes and longitudinal tracking, with unique attributes including:
- Research-focused registry design with patient consent
- Centralized follow-up for patient-reported outcome measures (PROMs) completion
- Linkage to the BARB Biorepository for biological sample analysis
- Integration with standardized hemoanalyzer configuration
- Detailed adherence protocol to ensure high-quality data collection
AAOS has partnered with Elimu Informatics and PatientIQ to develop the technical infrastructure for the OBR. Elimu provides analysis and design support, establishing the registry model using the AAOS Master Data Dictionary and tools, while PatientIQ has developed a cloud-based registry consistent with OBR data specifications that facilitate the input of procedure and patient-reported outcomes data.
The OBR is a unique offering within the AAOS family of registries, developed with support from the American Orthopaedic Society for Sports Medicine, the Arthroscopy Association of North America, and the Biologic Association.
In 2019, AAOS announced a strategic investment in the field of biologics. Over the following five years, the Academy prioritized research and development for a biologics-focused competency within its existing business. The focus of this effort has been to create evidence-based, unbiased information as tracked by the AAOS Biologics Dashboard; thought-leadership, position statements; and educational content to help shape and guide orthopaedic surgeons and their patients within this space.
The launch of the AAOS OBR represents the next phase of this commitment and comes at a pivotal time. The convergence of an aging population, rising obesity rates, and greater emphasis on staying active continues to drive demand for innovative orthobiologic treatment options. With over 18% of the population over age 55 experiencing symptomatic knee osteoarthritis3, the social and physical impact of this condition continues to be widespread.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
